Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12449536 | 0.77 | LMNA (0.33) | LMNAPOLB | |
| SCHEMBL15375204 | 0.74 | KDM4E (0.32) | POLB | |
| SCHEMBL21935852 | 0.73 | POLB (0.33) | LMNAPOLB | |
| SCHEMBL16743583 | 0.73 | KDM4E (0.31) | POLB | |
| SCHEMBL19221149 | 0.71 | AOC3 (0.31) | — | |
| Lithium SCHEMBL30033164 | 0.70 | LMNA (0.37) | LMNAPOLB | |
| SCHEMBL675972 | 0.70 | ALDH1A1 (0.38) | — | |
| SCHEMBL30033759 | 0.70 | LMNA (0.37) | LMNAPOLB | |
| SCHEMBL22122123 | 0.70 | — | — | |
| Potassium SCHEMBL30034109 | 0.70 | LMNA (0.37) | LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285985-A | Low-dynamic surface tension insulating layer buffer cleaning liquid and preparation method and application thereof | 四川格林达电子材料有限公司 | 2023-12-26 | — | — | CN | claimed |
| US-12454529-B2 | Piperazine cyclic ureas | Sironax Ltd. (KY) | 2025-10-28 | — | — | US | disclosed |
| WO-2025129135-A2 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-115697991-B | Piperazine cyclic ureas | 维泰瑞隆有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-117285985-A | Low-dynamic surface tension insulating layer buffer cleaning liquid and preparation method and application thereof | 四川格林达电子材料有限公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-3626699-B1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2023-07-12 | — | — | EP | disclosed |
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-115697991-A | Piperazine cyclic ureas | 维泰瑞隆有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2008074991-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008042925-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20070167442-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1691810-A1 | SUBSTITUTED PIPERAZINES | ChemoCentryx Inc (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20040162282-A1 | Substituted piperazines | CHEMOCENTRYX, INC. | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454529-B2 | Piperazine cyclic ureas | RIPK1, RIPK3, RIPK4 | LMNA 2733/4885POLB 2439/4885 |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | LMNA 4413/4885POLB 2547/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | LMNA 4351/4885POLB 2884/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | LMNA 4351/4885POLB 2884/4885 |
| US-20230203019-A1 | Piperazine Cyclic Ureas | RIPK1, RIPK3, RIPK4 | LMNA 2733/4885POLB 2439/4885 |
| US-20040162282-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | LMNA 4218/4885POLB 3493/4885 |
| US-20070167442-A1 | Chemical compounds | CCR5, CXCR3, CX3CR1 | LMNA 3639/4885POLB 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.